Barrett's esophagus is an increasingly common disease that is strongly associated with reflux of stomach acid and usually a hiatus hernia, and it strongly predisposes to esophageal adenocarcinoma (EAC), a tumor with a very poor prognosis. We report the first genome-wide association study on Barrett's esophagus, comprising 1,852 UK cases and 5,172 UK controls in the discovery stage and 5,986 cases and 12,825 controls in the replication stage. Variants at two loci were associated with disease risk: chromosome 6p21, rs9257809 (P combined = 4.09 × 10 −9 ; odds ratio (OR) = 1.21, 95% confidence interval (CI) =1.13-1.28), within the major histocompatibility complex locus, and chromosome 16q24, rs9936833 (P combined = 2.74 × 10 −10 ; OR = 1.14, 95% CI = 1.10-1.19), for which the closest protein-coding gene is FOXF1, which is implicated in esophageal development and structure. We found evidence that many common variants of small effect contribute to genetic susceptibility to Barrett's esophagus and that SNP alleles predisposing to obesity also increase risk for Barrett's esophagus.
Barrett's esophagus is one of the most common premalignant lesions in the western world. It affects over 2% of the adult population and, unlike bowel polyps, lacks any proven effective therapy 1 . In the majority of cases, Barrett's esophagus is associated with chronic gastroesophageal reflux disease (GERD), including esophagitis 2, 3 . Over 80% of affected individuals have a hiatus hernia in the lower esophagus that facilitates the reflux of acid and bile into the esophagus 4 . The measured annual risk of EAC in individuals with Barrett's esophagus varies widely but is approximately 0.4-1% (refs. 5-7). Notably, the incidence of EAC has been rising by 3% each year for the last 30 years; it is now the fifth most common cancer in the UK 8 . Despite modern multimodality therapy, the prognosis for EAC remains poor, with a 9-15% 5-year survival rate 9, 10 .
The etiology of Barrett's esophagus is not well characterized. Environmental factors, such as diet, are weakly associated with GERD, Barrett's esophagus and EAC, and obesity is a known risk factor for all three conditions 11 . There is also evidence implicating genetic factors: relative risks are increased by 2-to 4-fold for GERD, Barrett's esophagus and EAC when one first-degree relative is affected [12] [13] [14] [15] [16] [17] . A segregation analysis of 881 pedigrees of familial Barrett's esophagus supports an incompletely dominant inheritance model with a polygenic component 18 . Extensive candidate gene and linkage searches have to date been unsuccessful in identifying genetic variants that are associated with risk of Barrett's esophagus 19 .
As part of the Wellcome Trust Case Control Consortium 2 (WTCCC2) study of 15 common disorders and traits, we present the results of the first genome-wide association study of Barrett's esophagus susceptibility. Using a discovery cohort from the UK (with case samples from the Aspirin and Esomeprazole Chemoprevention Trial of Cancer in Barrett's esophagus (AspECT)) 20 and five replication cohorts (including case samples from CHemoprevention Of Premalignant Intestinal Neoplasia (ChOPIN) and Esophageal Adenocarcinoma GenEtics Consortium (EAGLE) studies 9, 20 ) , we identified two variants associated with Barrett's esophagus, each with combined evidence at P < 5 × 10 −8 . The analysis workflow is outlined in Supplementary Figure 1 , and characteristics of the case and control samples that were included can be found in the Online Methods and Supplementary Table 1. For the discovery analysis, cases with histologically confirmed Barrett's esophagus (Online Methods) were recruited from sites across the UK (Supplementary Table 2 ). Population controls were taken from the WTCCC2 common set of 1958 Birth Cohort (58C) and National Blood Service (UKBS) samples as previously described 21 .
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus 1 A full list of authors and affiliations appears at the end of the paper. 2 A full list of members and affiliations is provided in the Supplementary Note. Figure 1 Plot of the genome-wide association results after fitting the multiplicative model in SNPTEST. Results are shown for the 521,744 SNPs that passed quality control filters. Chromosomes are labeled on the x axis. The y axis shows the −log 10 P association values. Regions in red show the loci newly identified to be associated with Barrett's esophagus (described in Table 1 ).
l e T T e r S npg 1 1 3 2 VOLUME 44 | NUMBER 10 | OCTOBER 2012 Nature GeNetics l e T T e r S Cases were genotyped on the Illumina 660W-Quad array, and controls were genotyped on the Illumina custom Human 1.2M-Duo array, with analysis performed on the overlapping set of SNPs. After quality control (Online Methods, Supplementary Fig. 2 , Supplementary  Table 3 and Supplementary Note), a total of 521,744 SNPs typed in 1,852 cases and 5,172 controls (2,499 UKBS and 2,673 58C) were included in the discovery analysis. Association analysis was carried out under a logistic regression model implemented in SNPTEST. The genomic overdispersion factor 22 λ was 1.10, and this was reduced to 1.05 when the first principal component was incorporated as a covariate, suggesting that population structure was not a major confounder in the discovery analyses ( Supplementary  Fig. 3 ). For all of the following results presented, unless otherwise stated, the first principal component was used as a covariate.
After analysis of the genome-wide association results ( Fig. 1) , we adopted a staged approach to replication (outlined below and in Supplementary Fig. 1 ).
In stage 1, 100 SNPs that showed evidence of association in the discovery data (at P < 5 × 10 −4 ) were analyzed in another UK sample set. This comprised 1,105 cases from ChOPIN and EAGLE and 4,421 controls from the 58C control data set, all of which were genotyped on the Illumina Immunochip 23 (WTCCC2 contributed SNPs to the Immunochip design to allow for its replication studies, and the set of 100 SNPs followed up in our stage 1 replication were all on the Immunochip), and an additional set of 2,578 UK controls (the People of the British Isles (PoBI) collection) 24 In stage 3, two SNPs with P combined < 5 × 10 −8 after stage 2 replication (rs9257809 on chromosome 6p21 and rs9936833 on chromosome 16q24) were studied in three additional replication sample sets. They were directly genotyped in an Irish cohort of 245 cases and 473 controls and a UK cohort of 1,765 cases and 1,586 controls, and data for these SNPs were retrieved from the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium (BEACON) for 2,398 cases and 2,167 controls from European, Australian and US individuals with European ancestry.
After these three stages of replication, the two SNPs on chromosomes 6p21 and 16q24 showed compelling evidence for association, with combined P values of 4.09 × 10 −9 for rs9257809, OR (95% CI) = 1.21 (1.13-1.28), and 2.74 × 10 −10 for rs9936833, OR (95% CI) = 1.14 (1.10-1.19) (Figs. 2 and 3 and Table 1 ).
We performed tests for pairwise interaction (Supplementary Note) in the discovery data between all pairs of the 16 SNPs taken forward to stage 2 replication (Supplementary Table 5 ), but no significant interactions (P < 0.01) were found.
Imputation was carried out in the discovery data for the chromosome 6p21 and 16q24 regions, using the 1000 Genomes Project June 2010 Utah residents of Northern and Western European ancestry (CEU) reference panel. In each case, rs9257809 and rs9936833 remained the strongest signal of association in the corresponding genomic region ( Supplementary Fig. 4 ).
The lead SNP at 16q24, rs9936833, maps 24 kb away from the spliced, non-coding LOC732275 transcript. The closest coding gene, 141 kb toward the telomere, is FOXF1, a forkhead family transcription factor that acts in the Hedgehog signaling pathway. The FOXF1 protein is known to have a role in development of the gastrointestinal tract and has been reported to cause esophageal structural alterations, especially atresia, when inactivated 25 . The region around rs9936833 contains multiple binding sites for specific transcription factors, such as FOXP2, that are known to control FOXF1 expression (assessed using Encyclopedia of DNA Elements (ENCODE) data; see URLs).
The lead SNP at 6p21, rs9257809, lies on the telomeric edge of the major histocompatibility complex (MHC) region between olfactory receptor genes OR2D12 and OR2D13. The effect size and 95% CI are shown to the right of the cohort name for the discovery and replication cohorts and for the fixed-effects meta-analysis. The red dashed lines mark the effect size calculated from the fixed-effects meta-analysis. The P value for each cohort is shown at the right of the plot, and the meta-analysis P value is also given. All P values are two sided. Table 1 ). SNPs are colored on the basis of their r 2 values with the labeled lead SNP, which had the smallest P value in the region. r 2 values were calculated from the 58C data. The bottom section of each plot shows the fine-scale recombination rates estimated from individuals in the HapMap population, and genes are marked by horizontal blue arrows and arrowheads.
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It is in strong long-range linkage disequilibrium (LD; r 2 > 0.6, calculated in the control data) with SNPs over 1 Mb away, including two at which stage 2 replication was attempted: rs13211507 (P combined = 8.77 × 10 −9 ) and rs9262143 (P combined = 2.18 × 10 −8 ). When conditioning on rs9257809, no other SNP in the MHC region was associated with significance of P < 1 × 10 −5 .
To further investigate the SNP signal in the MHC region, we took two approaches: GENECLUSTER, which is a Bayesian tree building method 26, 27 , and HLA*IMP, which is a method for imputing classical human leukocyte antigen (HLA) alleles from SNP data 28 . Both methods provided evidence of association in the discovery data for reduced risk conferred by three classical HLA alleles that are in strong LD with each other (HLA-C*07:01, HLA-A*01:01 and HLA-B*08:01) (Supplementary Table 6 ). However, conditional analysis suggested that rs9257809 better captured the association in our discovery data, and none of these three classical HLA alleles showed an association signal in the replication data (P >0.1; Supplementary Table 6) .
We used standard UK criteria, in accordance with the British Society of Gastroenterology, for diagnosis of Barrett's esophagus. However, some countries use the American College of Gastroenterology criteria that require the presence of intestinal metaplasia for diagnosis with Barrett's esophagus. In order to investigate the effect of having included non intestinal metaplasia cases, we analyzed the two replicated loci, using only the subset of discovery and replication cases with histological evidence of intestinal metaplasia (86%). Both signals remained significant, with combined evidence across discovery and all stages of replication of P < 5 × 10 −8 (Supplementary Table 7a,b) .
We also investigated associations with the related quantitative traits of circumferential extent (C) and maximal extent (M) of the length of the Barrett's segment. In the discovery cohort, the C measurement was available for 1,744 cases, and the M measurement was available for 1,618 cases. In a linear regression analysis of cases, neither SNP showed evidence of association with C or M status (for rs9936833, P = 0.63 and 0.87, respectively; for rs925809, P = 0.10 and 0.09, respectively). We then extended the C and M analysis across the genome. No SNP reached P < 1 × 10 −6 in the analysis of C. One SNP (rs1023313) reached P < 1 × 10 −6 in the analysis of M, but this association was not confirmed in stage 1 or stage 2 replication (Supplementary Table 8 ).
There is an established sex bias in susceptibility to Barrett's esophagus, with men being at greater risk than women 3, 29 . The ratio of males to females was 4:1 in our case discovery data. To determine whether there might be sex-specific effects of any predisposition SNPs, we performed a sex-stratified analysis for the 16 SNPs analyzed in stage 2 (Supplementary Table 9 ). The SNP showing the most evidence for a sex-specific effect from the combined discovery set and stage 1 and 2 replication was rs9257809. The association signal was stronger in males than females (uncorrected P = 0.01 for the difference of effects between sexes), corresponding to a male odds ratio of 1.38 (95% CI = 1.25-1.53; P combined = 1.71 × 10 −10 ) and a female odds ratio of 1.11 (95% CI = 0.95-1.30; P combined = 0.19) (see Supplementary Note for further details). This finding warrants further investigation. Previous genome-wide association studies of common diseases or phenotypes have found evidence for a model where many common variants of small effect influence risk 30, 31 . We looked for these combined effects in Barrett's esophagus using two methods (Online Methods). First, taking the top k SNPs (for different values of k) in independent regions in the discovery data, we performed a sign test to determine whether there was an excess (over the proportion expected under the null of 50%) of SNPs for which the effect was in the same direction in the stage 1 replication data. Second, a disease score test analysis was undertaken, as described by the International Fig. 5 ). From the disease score analysis, the strongest evidence was for the top 1,710 SNPs, with P uncorrected = 7.07 × 10 −11 ( Supplementary  Fig. 6 ). Both analyses thus implicate a large number of common SNPs of small effect in susceptibility to Barrett's esophagus.
There is a well-established link between Barrett's esophagus and obesity 32, 33 . To investigate whether this link may in part reflect genetic effects, we repeated the sign test at 40 of the SNPs that have been found to be associated with either body mass index (BMI) or waisthip ratio (WHR) where genotype data or tag SNPs were available in our discovery samples [34] [35] [36] [37] [38] . In our discovery data, a total of 29 out of 40 BMI-and/or WHR-associated SNPs (14 genotyped, 15 tagging; Supplementary Table 10a,b) shared the same risk alleles in Barrett's esophagus as they did for BMI and/or WHR (P = 6.42 × 10 −3 ).
Our results provide direct evidence that Barrett's esophagus etiology has a genetic component. Inference of the underlying genes must be undertaken cautiously, especially for the variant (tagged by rs9257809) in the gene-rich MHC region in which LD is longrange and complex. However, the location of the other associated SNP, rs9936833, near FOXF1 suggests a role for structural factors in the esophagus and stomach as disease-predisposing factors, consistent with the fact that changes such as hiatus hernia are known to be strongly associated with Barrett's esophagus. We also found evidence to show that SNPs associated with body weight measures are more likely than expected by chance to show effects in the same direction in association with Barrett's esophagus, suggesting that genetic effects may in part underpin the epidemiological observation that BMI is a risk factor for Barrett's esophagus 39 . Given that Barrett's esophagus has an accepted status as a precursor lesion, the SNPs that we have identified could also essentially be risk factors for EAC and may give clues as to the biology of both of these important phenotypes.
URLs. SNPTEST, https://mathgen.stats.ox.ac.uk/genetics_software/ snptest/snptest.html; IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/ impute_v2.html; 1000 Genomes Project, http://www.1000genomes.org/; ENCODE, http://genome.ucsc.edu/encode/.
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SNP imputation was performed using IMPUTE2 (ref. 47) , which adopts a two-stage approach using both a haploid reference panel and a diploid reference panel.
BEACON data were analyzed under an additive logistic regression model, including the first four principal components as covariates (Supplementary Note). Genomic inflation λ was 1.037.
Combined analysis was carried out on the discovery and stage 1 data. To reduce possible population structure (such analyses are sensitive to this), we restricted the stage 1 control set to the 58C individuals. SNPs with minor allele frequency of >0.01 that were genotyped in both the discovery (Illumina 670K and Illumina custom Human 1.2M-Duo arrays) and the replication (Illumina Immunochip) stages were pruned to remove strong LD. This was done by ranking the SNPs by Bayes factor calculated under an additive model in SNPTEST and successively selecting SNPs from the top, requiring that they be at least 0.125 cM and 25 kb away from any SNPs that had already been selected. We obtained 7,673 SNPs from a total of 28,972 (after quality control) that were typed in discovery and UK Immunochip data. For the k SNPs showing the strongest signal of association, the sign test compared the direction of effect of each SNP in the discovery and replication samples. Using a likelihood-ratio test, we compared the null model where the probability of the same direction of effect is assumed to be 0.5 to a model where the probability is not 0.5 (two sided).
The disease score test aims to measure indirectly the collective effect of many weakly associated alleles. We determined the risk allele and odds ratio for each pruned SNP from the discovery data. Then, we used the top k SNPs to calculate the 'score' for each individual in the replication data as the number of risk alleles carried by each individual weighted by the log of the odds ratio estimated from the discovery data. Under the null hypothesis, the risk alleles and odds ratios in the discovery and replication samples are independent. We tested a logistic regression model of disease status on the score in the replication data, conditioning on the first principal component, to control for population structure, and the number of missing genotypes (called with maximum probability of <0.9), to control for potential differences in genotyping rate, as covariates.
